Guardant Health
GH
#3559
Rank
NZ$4.98 B
Marketcap
$40.55
Share price
-1.18%
Change (1 day)
-12.26%
Change (1 year)
Guardant Health is an American company developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors.

Guardant Health (GH) - Cash on Hand

Cash on Hand as of June 2024 : NZ$1.67 B

According to Guardant Health 's latest financial reports the company has NZ$1.67 B in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Guardant Health - Cash on Hand chart (from 2017 to 2024)

Cash on Hand by year

Year Cash on Hand Change
2023-12-31NZ$1.84 B16.02%
2022-12-31NZ$1.59 B16.94%
2021-12-31NZ$1.36 B-45.43%
2020-12-31NZ$2.49 B222.01%
2019-12-31NZ$0.77 B24.14%
2018-12-31NZ$0.62 B100.34%
2017-12-31NZ$0.31 B126.61%
2016-12-31NZ$0.13 B

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
NZ$1.43 B-14.31%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.27 B-83.49%๐Ÿ‡บ๐Ÿ‡ธ USA